Retraction
The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
Paper Information
Record ID:
33882
Author(s):
Publication Date:
January 03, 2017
Retraction Date:
November 09, 2021
(4.0 years years ago)
Subjects:
Broad Categories:
Biology
Biology
Institutions:
- Department of Human Oncology, University of Wis consin School of Medicineand Public Health, 1111 Highland Avenue, Madison, WI 53705, USA
- Departmentof Medical Oncology and Therapeutics Research, City of Hope ComprehensiveCancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA
- ExperimentalPharmacology and Oncology Berlin-Buch GmbH, Robert-Roessle-Str. 10, 13125Berlin, Germany
Countries:
Article Type:
Publisher:
American Association for the Advancement of Science (AAAS)
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1126/scisignal.abn0168Additional Notes:
see also: https://pubpeer.com/publications/51FBF301F19C689D548558937B326C;
Citations (47)
47
Total Citations15
Post-Retraction(31.9%)
31
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
2
Within 30 days
9
Within 1 year
1
After 2+ years
1265
Days since retraction (latest)
Molecular Insights into HPV-Driven Cervical Cancer: Oncoproteins, Immune Evasion, and Epigenetic Modifications
Luciana Alexandra Pavelescu, Nicoleta Larisa Mititelu-Zafiu, Dana Elena Mîndru et al. (5 authors)
Microorganisms
Open Access
Published: Apr 2025
1265 days after retraction
The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer
Xun Hui Yeo, Vignesh Sundararajan, Zhengwei Wu et al. (13 authors)
Communications Biology
Open Access
Published: Jun 2023
11 citations
11 citations
590 days after retraction
Targeting AXL in mesothelioma: From functional characterization to clinical implication
Kinjal Bhadresha, Sheefa Mirza, Clement Penny et al. (4 authors)
Critical Reviews in Oncology/Hematology
Published: Jun 2023
2 citations
2 citations
569 days after retraction
Data from Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Yuya Haga, Ilaria Marrocco, Ashish Noronha et al. (13 authors)
Unknown Journal
Open Access
Published: Mar 2023
507 days after retraction
Data from Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Yuya Haga, Ilaria Marrocco, Ashish Noronha et al. (13 authors)
Unknown Journal
Open Access
Published: Mar 2023
507 days after retraction
AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers
Xiaobai Sun, Hong Chen, Shuling You et al. (11 authors)
Molecular and Clinical Oncology
Open Access
Published: Feb 2023
3 citations
3 citations
456 days after retraction
Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies
Rahul Bhattacharjee, Sabya Sachi Das, Smruti Sudha Biswal et al. (18 authors)
Critical Reviews in Oncology/Hematology
Open Access
Published: Apr 2022
133 citations
133 citations
146 days after retraction
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Marie-Anne Goyette, Jean‐François Côté
Cancers
Open Access
Published: Jan 2022
49 citations
49 citations
70 days after retraction
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer
Open Access
Published: Jan 2022
284 citations
284 citations
66 days after retraction
The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance
Maria L. Lotsberg, Kjersti Davidsen, Stacey D’mello Peters et al. (7 authors)
Springer eBooks
Published: Jan 2022
53 days after retraction
Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling.
Lin Yang, Travis Vander Steen, Ingrid Espinoza et al. (7 authors)
PubMed
Published: Jan 2022
53 days after retraction
Role of Tyrosine Kinase Receptors in Growth Factor Mediated Signal Transduction, with Specific Reference to MAPK/Rasand p13k-Akt Containing Pathways in Oncogenesis: A Qualitative Database Review
Chanjugaa Uthayakumar, Rajavarthani Sanjeev
American Journal of Molecular Biology
Open Access
Published: Jan 2022
53 days after retraction
HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms
Kumpati Premkumar, Ramar Vanajothi, Natarajan Srikanth et al. (6 authors)
Current Drug Targets
Published: Dec 2021
11 citations
11 citations
44 days after retraction
AXL Regulates Neuregulin1 Expression Leading to Cetuximab Resistance in Head and Neck Cancer
Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki et al. (10 authors)
Research Square (Research Square)
Open Access
Published: Dec 2021
27 days after retraction
Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation
Ji Hyang Kim, Hack-Sun Choi, Dong‐Sun Lee
International Journal of Molecular Sciences
Open Access
Published: Nov 2021
19 citations
19 citations
21 days after retraction
Retraction
Toni M. Brand, Mari Iida, Kelsey L. Corrigan et al. (11 authors)
Science Signaling
Open Access
Published: Nov 2021
Same day as retraction
AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
Almira Auyez, A. Emre Sayan, Marina Kriajevska et al. (4 authors)
Cancers
Open Access
Published: Sep 2021
38 citations
38 citations
42 days before retraction
Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors
Yuya Haga, Ilaria Marrocco, Ashish Noronha et al. (13 authors)
Cancer Research
Open Access
Published: May 2021
10 citations
10 citations
190 days before retraction
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Ilaria Marrocco, Donatella Romaniello, Itay Vaknin et al. (12 authors)
EMBO Molecular Medicine
Open Access
Published: Mar 2021
19 citations
19 citations
250 days before retraction
Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
Izhar Singh Batth, Shih‐Bo Huang, Michelle Villarreal et al. (17 authors)
International Journal of Molecular Sciences
Open Access
Published: Feb 2021
15 citations
15 citations
270 days before retraction
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj et al. (18 authors)
Cancers
Open Access
Published: Aug 2020
45 citations
45 citations
442 days before retraction
Nuclear IGF1R interact with PCNA to preserve DNA replication after DNA-damage in a variety of human cancers
Yang Chen, Yifan Zhang, Yi Chen et al. (14 authors)
PLoS ONE
Open Access
Published: Jul 2020
16 citations
16 citations
474 days before retraction
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Nellie K. McDaniel, Mari Iida, Kwangok P. Nickel et al. (20 authors)
Clinical Cancer Research
Open Access
Published: May 2020
38 citations
38 citations
537 days before retraction
AXL as a Target in Breast Cancer Therapy
Sierra A. Colavito
Journal of Oncology
Open Access
Published: Feb 2020
61 citations
61 citations
634 days before retraction
Patient Derived Models to Study Head and Neck Cancer Radiation Response
Pippa F. Cosper, Lindsey Abel, Yong-Syu Lee et al. (10 authors)
Cancers
Open Access
Published: Feb 2020
19 citations
19 citations
636 days before retraction
Paper citing The receptor tyrosine kinase AXL mediates nuclear ...
Unknown Authors
Unknown Journal
Published: Feb 2020
636 days before retraction
Patient Derived Models to Study Head and Neck Cancer Radiation Response
Pippa F. Cosper, Lindsey Abel, Yong-Syu Lee et al. (10 authors)
Unknown Journal
Open Access
Published: Feb 2020
3 citations
3 citations
638 days before retraction
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Chennianci Zhu, Weihao Zhuang, Limin Chen et al. (5 authors)
Translational Lung Cancer Research
Open Access
Published: Feb 2020
38 citations
38 citations
647 days before retraction
Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
Émerson Soares Veloso, Ivy Nayra Nascimento Gonçalves, Tatiany L. Silveira et al. (8 authors)
BMC Veterinary Research
Open Access
Published: Jan 2020
11 citations
11 citations
650 days before retraction
Patient Derived Models to Study Head and Neck Cancer Radiation Response
Pippa F. Cosper, Lindsey Abel, Yong-Syu Lee et al. (10 authors)
Unknown Journal
Open Access
Published: Jan 2020
5 citations
5 citations
659 days before retraction
TAM family proteins and therapy resistance
Nellie K. McDaniel, Samantha R. Fischbach, Olivia J. Ondracek et al. (6 authors)
Elsevier eBooks
Published: Jan 2020
1 citation
1 citation
678 days before retraction
Receptor Tyrosine Kinases in Osteosarcoma: 2019 Update
Edward M. Greenfield, Christopher D. Collier, Patrick J. Getty
Advances in experimental medicine and biology
Published: Jan 2020
12 citations
12 citations
678 days before retraction
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
Antonino Belfiore, Adele Busico, Fabio Bozzi et al. (16 authors)
International Journal of Molecular Sciences
Open Access
Published: Nov 2019
12 citations
12 citations
721 days before retraction
Research Progress of Axl Inhibitors
Zhigang Sun, Jianhua Liu, Jinmai Zhang et al. (4 authors)
Current Topics in Medicinal Chemistry
Published: Jun 2019
12 citations
12 citations
873 days before retraction
Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor
Xuezhu Rong, Yuan Liang, Qiang Han et al. (16 authors)
Journal of Thoracic Oncology
Open Access
Published: Jun 2019
36 citations
36 citations
874 days before retraction
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
Donghwa Kim, Duc‐Hiep Bach, Yanhua Fan et al. (7 authors)
Cell Death and Disease
Open Access
Published: May 2019
89 citations
89 citations
923 days before retraction
Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response
Mahmoud Toulany
Genes
Open Access
Published: Jan 2019
134 citations
134 citations
1040 days before retraction
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon, Minhee Ku, Jaemoon Yang
Experimental & Molecular Medicine
Open Access
Published: Jan 2019
166 citations
166 citations
1043 days before retraction
A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases
Ying‐Nai Wang, Heng‐Huan Lee, Mien‐Chie Hung
Journal of Biomedical Science
Open Access
Published: Nov 2018
14 citations
14 citations
1086 days before retraction
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
Eugene Tulchinsky, Oleg N. Demidov, Marina Kriajevska et al. (5 authors)
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Published: Nov 2018
185 citations
185 citations
1095 days before retraction
Does Axl have potential as a therapeutic target in pancreatic cancer?
Wenting Du, Rolf A. Brekken
Expert Opinion on Therapeutic Targets
Open Access
Published: Sep 2018
28 citations
28 citations
1142 days before retraction
Trafficking of Adhesion and Growth Factor Receptors and Their Effector Kinases
Christina Schoenherr, Margaret C. Frame, Adam Byron
Annual Review of Cell and Developmental Biology
Open Access
Published: Aug 2018
12 citations
12 citations
1182 days before retraction
ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
Yulin Wang, Gefei Guan, Wen Cheng et al. (8 authors)
BMC Cancer
Open Access
Published: May 2018
28 citations
28 citations
1260 days before retraction
HPV: Molecular pathways and targets
Shilpi Gupta, Prabhat Kumar, Bhudev C. Das
Current Problems in Cancer
Published: Mar 2018
166 citations
166 citations
1349 days before retraction
Axl inhibitors as novel cancer therapeutic agents
Yingying Shen, Xiguang Chen, Jun He et al. (5 authors)
Life Sciences
Published: Feb 2018
67 citations
67 citations
1351 days before retraction
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An, Ozlem Aksoy, Tina Zheng et al. (5 authors)
Oncogene
Open Access
Published: Jan 2018
535 citations
535 citations
1401 days before retraction
L’EGFR nucléaire : un nouveau mode de signalisation dans les cancers
Sylvie Gazzéri
Biologie Aujourd hui
Published: Jan 2018
18 citations
18 citations
1408 days before retraction
Quick Stats
Total Citations:
47
Years Since Retraction:
4.0 years
Open Access:
Yes
Last Checked:
Jul 24, 2025